Ligand Pharma (LGND) PT Raised to $332 at Stifel as Xoma Asset Acquisition Announced

July 8, 2026 7:22 AM

Stifel analyst Annabel Samimy raised the price target on Ligand Pharma (NASDAQ: LGND) to $332.00 (from $255.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found